Beigene Ltd is a biotechnology company focused on discovering and developing innovative medicines to improve treatment outcomes for patients with cancer. The company has a robust pipeline of targeted therapies and immuno-oncology products aimed at various types of malignancies. Beigene is committed to advancing cancer treatment through rigorous research and development efforts, collaborating with global partners, and ensuring access to its therapies for patients in need. By leveraging its scientific expertise and cutting-edge technologies, Beigene seeks to address significant unmet medical needs in the field of oncology.
The FDA's advisory committee is set to evaluate the use of PD-1 inhibitors in gastric cancer patients, focusing on the risks and benefits for those with varying PD-L1 levels, including low expressers.
JMP Securities has initiated coverage on BeiGene highlighting the Chinese biotech company as a 'unique investment opportunity.' The firm's leading drug, Brukinsa (zanubrutinib), is emerging in the competitive BTK inhibitor market.
Key Takeaways: Sales approval for the company’s anti-obesity drug mazdutide may drag out beyond this year, potentially allowing rival products to gain a market advantage The executive in charge of Innovent’s R&D activities dropped a bombshell on the eve of the earnings release, announcing his retirement
UCB announced plans to divest its current China five-drug portfolio, narrowing its China focus to commercialize soon-to-arrive late-stage clinical assets. It will sell this “mature” neurology and allergy portfolio for $680 million to CBC Group.
The FDA's Oncologic Drugs Advisory Committee will meet on September 26 to reevaluate the approvals of checkpoint inhibitors for advanced gastric, gastroesophageal junction adenocarcinoma, and esophageal squamous cell carcinoma.
Triastek will develop oral RNA therapeutics with Germany’s BioNTech based on its 3D printing technology. Triastek will receive a $10 million upfront payment and up to $1.2 billion in milestones, plus royalties.
Nurix Therapeutics presented updated clinical data for NX-5948, an orally bioavailable BTK degrader, at the EHA Congress. NX-5948 showed promising safety and efficacy in Phase 1a/b trials for relapsed/refractory B-cell malignancies
Shionogi, an Osaka innovative pharma, has signed an option agreement with Cilcare of France to in-license two drug candidates aimed at hearing loss in a deal worth up to $445 million. Meanwhile, XtalPi raised $126.8 million in a Hong Kong IPO.
10 worst-performing large-cap stocks last week. National Grid, James Hardie, KE Holdings, JD.Com, XP, Nordson, BeiGene, Lululemon, Walgreens, and Li Auto.
